title: Individualization of maintenance immunosuppressive therapy equalizes acute rejection risk in African American versus non-African American renal allograft recipients.
authors.affiliation: Department of Urology, Loyola University of Chicago Stritch School of Medicine, Maywood, Illinois 60153, USA.
authors.forename: R
authors.initials: R
authors.lastname: Lewis
authors.forename: J
authors.initials: J
authors.lastname: Coutee
authors.forename: B
authors.initials: B
authors.lastname: Kostro
authors.forename: D
authors.initials: D
authors.lastname: Calvert
authors.forename: C
authors.initials: C
authors.lastname: Cava-Bartsch
authors.forename: B
authors.initials: B
authors.lastname: Susskind
authors.forename: G
authors.initials: G
authors.lastname: Swies
authors.forename: T
authors.initials: T
authors.lastname: Burns
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D044383:Black People; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D044469:Racial Groups; D014481:United States; D001741:Black or African American
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3